The complement inhibitors market is projected to grow, driven by the rising prevalence of complement-mediated diseases, intensified R&D efforts, and biotechnological advancements enabling novel ...
Bartenders reveal the best whiskeys for a Manhattan, including ryes and bourbons like Rittenhouse and Booker’s, plus expert ...
Bean salads are hearty and flavorful. If you need some ideas for your next batch, check out some of our favorite bean salad ...
Sovereign wealth fund governance offers boards a framework of identity, alignment and long-term thinking to strengthen ...
The Chosun Ilbo on MSN
Justice minister: Indictment agency must complement investigations
Minister of Justice Jung Sung-ho stated on the 27th, “Investigations and records are organically connected and cannot be ...
A cash-rich tech player is quietly delivering strong returns and hefty dividends. But with rising AI investments and an ...
We spoke with chefs and restaurateurs in the key whiskey states of Kentucky and Tennessee to discover the best ways to use ...
Environments have no boundaries and no borders. Managing oceanic environments, particularly the threats and risks of ...
Perivascular adipose tissue (PVAT) has emerged as a significant player in the regulation of vascular health, complementing ...
A composable architecture that keeps customer data in-country from day one and outlasts the components inside it. SINGAPORE, ...
Chief Executive John Lee hails school's strategic role in turning city into healthcare and talent hub and aligning with ...
EMPAVELI (pegcetacoplan) is the first approved treatment for C3G or primary IC-MPGN for patients 12 years and older in Canada Approval supported by Phase 3 52-week VALIANT study demonstrated reduced p ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results